Study

Alzheimer’s Cortisol Study

Just one pill a day.

A New Approach To Fighting Alzheimer's

Charter Research is seeking volunteers in a new clinical trial of Xanamem, an oral medication designed to treat individuals with mild or moderate dementia due to Alzheimer’s. Xanamem was developed in response to evidence of a strong association between chronically-raised cortisol levels and the development of cognitive impairment in Alzheimer’s disease. The drug is designed to target and block production of cortisol inside brain neurons.

One study of Xanamem demonstrated that healthy, elderly individuals with higher cortisol levels were significantly more likely to develop Alzheimer’s disease than those with lower cortisol levels. The study authors concluded that therapies aimed at lowering cortisol levels should be considered as a potential way of addressing the development of Alzheimer’s disease.

Who is eligible?

You may qualify for this study if:

You are at least 50 years old.
You have mild or moderate dementia, likely to be due to Alzheimer's, in the opinion of the Principal Investigator.
You have a reliable study partner.

Sign Up

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.